Summary:
This is a diabetic study evaluating once weekly exenatide suspension therapy added to titrated insulin daily. Subjects will receive routine office visits, diet/exercise counseling, study medications, and routine labs including HbA1c. There are 14 in office visits and some phone visits.
Inclusions include:
- Subjects must have HbA1c between 7.5%-12% inclusive
- Subjects must be taking daily Lantus – may also be on stable dose of metformin (≥1500 mg/day)
Exclusions include:
- Any exposure to exenatide or currently taking Humalog or Novolog
- History of/or presence of inflammatory bowel disease, chronic pancreatitis, TRG ≥500mg/dL, gastric bypass or banding surgery or plans to do so during study, significant hepatic disease (Hep B/C), HIV +, severe CHF, significant cardiovascular disease/procedure within 3 months of screening
Call for further inclusion/exclusion info
Qualified Participants May Receive:
Compensation for time/travel of $1000 will be provided to qualified participants who complete the study